Patent Issued for 2,4-dinitrophenol formulations and methods using same (USPTO 11883369).

A patent has been issued to Yale University for 2,4-dinitrophenol (DNP) formulations and methods for treating various diseases and disorders. Non-alcoholic fatty liver disease (NAFLD) is a key factor in the development of type 2 diabetes and other conditions, and new therapies are needed. DNP is a mitochondrial uncoupling agent that promotes heat dissipation and energy expenditure. The patent describes methods of administering DNP in sustained-release formulations to treat NAFLD, non-alcoholic steatohepatitis (NASH), hepatic steatosis, type 2 diabetes, obesity, and other related conditions. The patent also mentions the potential use of DNP in combination with other therapeutic agents. [Extracted from the article]